Locations:
Search IconSearch

Neurosciences

Grabowski, MD
January 24, 2023/Cancer

Study Explores Optimal Dosage of Novel Combination Therapy for Recurrent Glioblastoma

Focused ultrasound is paired with ALA to utilize sonodynamic therapy to target cancer cells

22-NEU-3316415-Hero-Podcast-650×450
January 17, 2023/Behavioral Health

Predicting Neuropsychological Outcomes Following Temporal Lobe Epilepsy Surgery (Podcast)

Multivariable models help estimate risk of postoperative declines in cognition and mood

22-NEU-3482371 Alzheimers-brain-650×450
January 12, 2023/Neurosciences/Brain Health

Does Peripheral Inflammation Drive Alzheimer’s Disease Progression?

New research explores the role of immune cell and blood-brain barrier changes

22-NEU-3316414-CQD-Hero1-650×450
January 3, 2023/Neurosciences/Podcast

Diagnosis and Management of Autoimmune Encephalitis (Podcast)

Comprehensive evaluation and keen clinical judgment are key in suspected cases

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Brain research

Deep Learning Framework Unveiled for Identifying Risk Genes and Drug Targets in Alzheimer’s Disease

Open-source artificial intelligence technology uses human genetic data to find candidate drugs

22-NEU-3409069-CQD-Hero-650×450
December 20, 2022/Cancer

Survival Is Associated With Subsets of T Cells in Recurrent Glioblastoma Treated With SL-701

Can T-cell immunophenotyping help inform treatment decisions?

22-NEU-3316413-CQD-Hero2-650×450
December 16, 2022/Behavioral Health

Adjunctive Therapies for the Treatment of Headache (Podcast)

Chronic headache sufferers may benefit from adjuvant drugs, devices and procedures

22-NEU-3450073-CQD-Hero-650×450
December 13, 2022/Neurosciences/Brain Health

What’s the State of Anti-Amyloid Therapy in the Wake of Initial Clarity AD Findings?

Experts weigh in on the amyloid hypothesis and how to use lecanemab if approved

22-NEU-3409067_central-vein-sign_650x450

Central Vein Sign on FLAIR* MRI Comparable to CSF Oligoclonal Bands for Diagnosing MS

Initial pilot study findings suggest a potential reduced need for cerebrospinal fluid testing

22-NEU-3367462-T-cells-650×450
December 6, 2022/Cancer

Phase 1 Trial Shows Drug-Resistant Immunotherapy for Glioblastoma Is Safe and Feasible

Intracranial injection of supercharged immune cells proceeds to phase 2 testing

BackPage 35 of 84Next

Advertisement

Ad